Trial Profile
An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2021
Price :
$35
*
At a glance
- Drugs RZ 358 (Primary)
- Indications Hyperinsulinaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors XOMA
- 19 May 2021 Status changed from recruiting to completed.
- 23 Mar 2021 Results of population PK PD model analysis presented at the 103rd Annual Meeting of the Endocrine Society
- 22 Mar 2021 Results presented in a Rezolute Media Release.